Credit rating agency, CARE has revised ‘AA’ rating to Ranbaxy Laboratories’ Long-term Bank Facilities worth Rs 300 crore and Long-term Instrument (NCD) worth Rs 500 crore from AA+. The rating agency has also reaffirmed ‘A1+’Short-term Bank Facilities worth Rs 600 crore.
The company has received the said ratings on the back of its established position in the domestic pharmaceuticals market and in the global markets supported by a pipeline of Abbreviated New Drug Applications (ANDAs)
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.70 |
| Dr. Reddys Lab | 1224.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2315.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: